Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified ...